Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study.

Soyoon Hwang Nan Young Lee EunKyung Nam Yu Kyoung Kim Shin-Woo Kim Hyun Ha Chang Yoon Jung Kim Shin-Woo Kim Juhwan Jeong Jae-Ho Shin Guehwan Jang Changhee Lee Ki Tae Kwon

Published in: Infectious diseases and therapy (2024)

We showed that regdanvimab reduced the exacerbation rates of conditions and mortality in patients with the COVID-19 delta variant infection. Thus, it is recommended to streamline the drug approval system during epidemics of new variant viruses to improve the availability and usage of therapeutics for patients. To facilitate this, relevant institutional support is required.

Keyphrases

sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
peritoneal dialysis
cardiovascular disease
cardiovascular events
intensive care unit
respiratory syndrome coronavirus
mechanical ventilation